REGN logo Regeneron Pharmaceuticals +
Regeneron Pharmaceuticals
+

Regeneron Pharmaceuticals Overview

Company: Regeneron Pharmaceuticals
CEO: Leonard S. Schleifer
Symbol: REGN
Exchange: NASDAQ
Industry: Biotechnology
Sector: Healthcare
About

Regeneron Pharmaceuticals is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolioludes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes,luding familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners,luding Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Continue reading...

Regeneron Pharmaceuticals (REGN)

  • Stock Price
  • Volume
651.91 +74.13 +12.83%
Past 5 Years
  • 1D
  • 1W
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • 10Y
  • ALL

Revenue

Regeneron Pharmaceuticals annual revenue was $14.34 B in 2025.

Net Income

Regeneron Pharmaceuticals annual net income was $4.50 B in 2025.

Employees

Regeneron Pharmaceuticals annual employee count was 15,410 in 2025.

Revenue by Segment

Regeneron Pharmaceuticals’s revenue by segment: Collaboration Revenue: $7.33 B, Product: $6.31 B and Product and Service, Other: $702.60 M in 2025.

Revenue by Region

Regeneron Pharmaceuticals’s revenue by region: Rest Of World: $507.50 M and UNITED STATES: $4.38 B in 2025.

Executive Salary

Daniel P. Van Plew Executive Vice President and General Manager, Ind...

Revenue per Employee

Regeneron Pharmaceuticals revenue per employee was $930.75 K in 2025.

Profit per Employee

Regeneron Pharmaceuticals profit per employee was $292.34 K in 2025.

Income Statement

Operating Income

Regeneron Pharmaceuticals annual operating income was $3.69 B in 2025.

Research & Development

Regeneron Pharmaceuticals annual research & development expense was $5.85 B in 2025.

Tax Rate (%)

Regeneron Pharmaceuticals annual Tax Rate was 14.00% in 2025.

Assets & Liabilities | Cash Flow

Total Assets

Regeneron Pharmaceuticals annual total assets was $40.56 B in 2025.

Total Liabilities

Regeneron Pharmaceuticals annual total liabilities was $2.75 B in 2025.

Capital Expenditure

Regeneron Pharmaceuticals annual capital expenditures was -$898.40 M in 2025.

Ratios

Return on Equity (ROE)

Regeneron Pharmaceuticals annual return on equity(ROE) was 14.41% in 2025.

Return on Assets (ROA)

Regeneron Pharmaceuticals annual return on assets(ROA) was 11.11% in 2025.

Debt to Equity

Regeneron Pharmaceuticals annual debt to equity was 8.66% in 2025.

Profitability

Gross Profit Margin (%)

Regeneron Pharmaceuticals annual gross profit margin was 86.27% in 2025.

Operating Income Margin (%)

Regeneron Pharmaceuticals annual operating income margin was 25.75% in 2025.

Net Income Margin (%)

Regeneron Pharmaceuticals annual net income margin was 31.41% in 2025.

Earning Per Share

Regeneron Pharmaceuticals annual earning per share was $43.07 in 2025.

EBITDA

Regeneron Pharmaceuticals annual EBITDA was $5.27 B in 2025.

Free Cash Flow (FCF)

Regeneron Pharmaceuticals annual free cash flow(FCF) was $4.08 B in 2025.

Valuation

Enterprise value

Regeneron Pharmaceuticals annual enterprise value was $83.44 B in 2025.

Enterprise value to Revenue

Regeneron Pharmaceuticals annual enterprise value to revenue was 5.82 in 2025.

Enterprise value to EBITDA

Regeneron Pharmaceuticals annual enterprise value to EBITDA was 15.82 in 2025.

Competitors’ Revenue

Frequently Asked Questions

Who is the CEO of Regeneron Pharmaceuticals?

Leonard S. Schleifer is the CEO of Regeneron Pharmaceuticals.

What industry and sector is Regeneron Pharmaceuticals in?

Regeneron Pharmaceuticals operates in the Biotechnology industry and the Healthcare sector.

What are Regeneron Pharmaceuticals's CIK, SIC, and ISIN codes?

  • CIK (Central Index Key): 0000872589
  • SIC (Standard Industrial Classification): 2834
  • ISIN (International Securities Identification Number): US75886F1075

Sign up for free to view

How many employees does Regeneron Pharmaceuticals have?

Regeneron Pharmaceuticals has 15,410 employees.

What is the revenue of Regeneron Pharmaceuticals?

In fiscal year 2025, Regeneron Pharmaceuticals generated a revenue of $14.34 Billion.

What is the net income of Regeneron Pharmaceuticals?

In fiscal year 2025, Regeneron Pharmaceuticals reported a net income of $4.50 Billion.

What is Regeneron Pharmaceuticals's biggest product segment?

Collaboration Revenue is Regeneron Pharmaceuticals's biggest product segment, representing 51.11% of its total revenue.

When was Regeneron Pharmaceuticals listed on the stock exchange?

Regeneron Pharmaceuticals went public on Apr 2, 1991, through its Initial Public Offering (IPO), and it has been 35 years since then.

Sign up for free to view

What is the ticker symbol of Regeneron Pharmaceuticals, and where is it listed?

Regeneron Pharmaceuticals's ticker symbol is REGN, and the company is listed on the NASDAQ stock market exchange.

What is Regeneron Pharmaceuticals's current stock price?

Regeneron Pharmaceuticals's current stock price is $652.08 as of Jul 24, 2026.

What is Regeneron Pharmaceuticals's market capitalization?

As of , Regeneron Pharmaceuticals's market cap is .

What is Regeneron Pharmaceuticals's ranking in the world?

Ranked #29among 2,823 companies based on market cap.

Who are the top competitors of Regeneron Pharmaceuticals?

Competitors of Regeneron Pharmaceuticals include Moderna, and more.

People Also Search For

Submit feedback to Bullfincher